• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of the advanced practitioner in oncology >Thoracic Cancer: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner: The Advanced Practitioner Perspective: Sotorasib: Subgroup Analysis of Phase II Trial Shows Activity With Breakthrough KRAS Inhibitor in Lung Cancer, By Alice Goodman
【24h】

Thoracic Cancer: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner: The Advanced Practitioner Perspective: Sotorasib: Subgroup Analysis of Phase II Trial Shows Activity With Breakthrough KRAS Inhibitor in Lung Cancer, By Alice Goodman

机译：Thoracic Cancer: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner: The Advanced Practitioner Perspective: Sotorasib: Subgroup Analysis of Phase II Trial Shows Activity With Breakthrough KRAS Inhibitor in Lung Cancer, By Alice Goodman

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相关主题

摘要

The breakthrough KRAS-specific inhibitor sotorasib achieved responses in patients with KRAS G12C–mutated non–small lung cancer (NSCLC) who had experienced disease progression on platinum-based chemotherapy, immunotherapy, or both treatments. The objective response rate was 37.1%, and responses extended to all subgroups, according to an analysis of the phase II CodeBreaK 100 trial study presented at the 2021 ASCO Annual Meeting by lead study author Ferdinandos Skoulidis, MD, PhD, Assistant Professor of Thoracic Medical Oncology, at The University of Texas MD Anderson Cancer Center, Houston.1 A confirmatory phase III CodeBreaK 200 trial is designed to compare sotorasib vs docetaxel. The first report from the study suggested that patients with co-mutations in STK11, a driver of poor outcomes with standard care, derived benefit from sotorasib.2 The extended subgroup analysis presented at the ASCO meeting showed a numerically higher response rate and longer progression-free and overall survival in patients with STK11 co-mutated but KEAP1 wild-type disease. Due to the small number of patients, further study is needed to determine which subgroups—if any—have more robust responses to sotorasib. The Advanced Practitioner Perspective: The findings from the clinical trial with sotorasib are exciting for patients with Kirsten rat sarcoma (KRAS) mutation, which was once felt to be difficult to treat and not sensitive to treatment. KRAS mutation is the most prevalent driver mutation in NSCLC and is found in 25% to 30% of nonsquamous NSCLCs (Biernacka et al., 2016; Boch et al., 2013; Riely et al., 2008). Of all the KRAS mutations, G12C is the most frequent variant in NSCLC, with a prevalence of 13% in lung adenocarcinomas (Biernacka et al., 2016). The findings from the clinical trial showed the effectiveness of sotorasib in patients previously treated with chemotherapy, immunotherapy, or both chemotherapy and immunotherapy. Patients with STK11 mutations also derived benefit from sotorasib, although further study is needed. Toxicities from sotorasib are similar to those with other oral targeted therapies. Once again, there is reason for excitement in thoracic oncology, as there is a new, effective targeted therapy—sotorasib—for a mutation once thought to be undruggable. Sotorasib appears to have some efficacy for STK11 mutations, giving hope to patients who have this mutation, although more studies are needed to validate these findings.

著录项

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号